Elevated CEA levels in patients with cancer-causing factors are linked to their resistance to EGFR-tyrosine kinase inhibitors (TKIs), underscoring the necessity for more treatment approaches to counteract resistance [52]. Here, CEACAM5 is linked to cancer.